204 related articles for article (PubMed ID: 34896887)
1. Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies.
Arase N; Tsuji H; Takamatsu H; Jin H; Konaka H; Hamaguchi Y; Tonomura K; Kotobuki Y; Ueda-Hayakawa I; Matsuoka S; Hirano T; Yorifuji H; Murota H; Ohmura K; Nakashima R; Sato T; Kumanogoh A; Katayama I; Arase H; Fujimoto M
J Autoimmun; 2022 Jan; 126():102774. PubMed ID: 34896887
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K
Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
[TBL] [Abstract][Full Text] [Related]
3. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
Xing X; Li A; Li C
Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
[TBL] [Abstract][Full Text] [Related]
4. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies.
Frank MB; McCubbin V; Trieu E; Wu Y; Isenberg DA; Targoff IN
J Autoimmun; 1999 Mar; 12(2):137-42. PubMed ID: 10047434
[TBL] [Abstract][Full Text] [Related]
5. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52.
Yamasaki Y; Satoh M; Mizushima M; Okazaki T; Nagafuchi H; Ooka S; Shibata T; Nakano H; Ogawa H; Azuma K; Maeda A; Tonooka K; Ito H; Takakuwa Y; Inoue M; Mitomi H; Kiyokawa T; Tsuchida K; Matsushita H; Mikage H; Murakami Y; Chan JY; Ozaki S; Yamada H
Mod Rheumatol; 2016; 26(3):403-9. PubMed ID: 26344678
[TBL] [Abstract][Full Text] [Related]
6. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
Sabbagh S; Pinal-Fernandez I; Kishi T; Targoff IN; Miller FW; Rider LG; Mammen AL;
Ann Rheum Dis; 2019 Jul; 78(7):988-995. PubMed ID: 31018961
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
9. [Correlation study on anti-Ro52 antibodies frequently co-occur with other myositis-specific and myositis-associated autoantibodies].
Zheng YM; Hao HJ; Liu YL; Guo J; Zhao YW; Zhang W; Yuan Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1088-1092. PubMed ID: 33331318
[TBL] [Abstract][Full Text] [Related]
10. Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.
Chan EKL
Clin Rev Allergy Immunol; 2022 Oct; 63(2):178-193. PubMed ID: 35040083
[TBL] [Abstract][Full Text] [Related]
11. Myeloperoxidase/HLA Class II Complexes Recognized by Autoantibodies in Microscopic Polyangiitis.
Hiwa R; Ohmura K; Arase N; Jin H; Hirayasu K; Kohyama M; Suenaga T; Saito F; Terao C; Atsumi T; Iwatani H; Mimori T; Arase H
Arthritis Rheumatol; 2017 Oct; 69(10):2069-2080. PubMed ID: 28575531
[TBL] [Abstract][Full Text] [Related]
12. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies.
Leclair V; Galindo-Feria AS; Rothwell S; Kryštůfková O; Zargar SS; Mann H; Diederichsen LP; Andersson H; Klein M; Tansley S; Rönnblom L; Lindblad-Toh K; Syvänen AC; Wahren-Herlenius M; Sandling JK; ; McHugh N; Lamb JA; Vencovský J; Chinoy H; Holmqvist M; Bianchi M; Padyukov L; Lundberg IE; Diaz-Gallo LM
EBioMedicine; 2023 Oct; 96():104804. PubMed ID: 37769433
[TBL] [Abstract][Full Text] [Related]
13. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
[TBL] [Abstract][Full Text] [Related]
14. New-onset dermatomyositis following COVID-19: A case report.
Shimizu H; Matsumoto H; Sasajima T; Suzuki T; Okubo Y; Fujita Y; Temmoku J; Yoshida S; Asano T; Ohira H; Ejiri Y; Migita K
Front Immunol; 2022; 13():1002329. PubMed ID: 36353621
[TBL] [Abstract][Full Text] [Related]
15. An effective algorithm for the serological diagnosis of idiopathic inflammatory myopathies: The key role of anti-Ro52 antibodies.
Infantino M; Manfredi M; Grossi V; Benucci M; Morozzi G; Tonutti E; Tampoia M; Bizzaro N
Clin Chim Acta; 2017 Dec; 475():15-19. PubMed ID: 28986052
[TBL] [Abstract][Full Text] [Related]
16. Associations of MHC class II alleles in Norwegian primary Sjögren's syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen.
Nakken B; Jonsson R; Brokstad KA; Omholt K; Nerland AH; Haga HJ; Halse AK
Scand J Immunol; 2001 Oct; 54(4):428-33. PubMed ID: 11555411
[TBL] [Abstract][Full Text] [Related]
17. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
[TBL] [Abstract][Full Text] [Related]
18. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.
Kryštůfková O; Barbasso Helmers S; Venalis P; Malmström V; Lindroos E; Vencovský J; Lundberg IE
Arthritis Res Ther; 2014 Oct; 16(5):454. PubMed ID: 25301447
[TBL] [Abstract][Full Text] [Related]
19. Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study.
Vázquez-Del Mercado M; Martínez-García EA; Daneri-Navarro A; Gómez-Bañuelos E; Martín-Márquez BT; Pizano-Martínez O; Wilson-Manríquez EA; Corona-Sánchez EG; Chavarria-Avila E; Sandoval-García F; Satoh M
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):328-333. PubMed ID: 33876712
[TBL] [Abstract][Full Text] [Related]
20. Management of Myositis-Associated Interstitial Lung Disease.
Fujisawa T
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
